Down-regulation Tim3 has an additive effect of bortezomib on the NF-κB signal pathway and then inhibit proliferation and induce apoptosis of MM cells, suggesting that Tim3 may be a potential therapeutic target for MM. This evidence concerns the gene NFKB1 and Miyoshi myopathy.